Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SD-101 + paclitaxel + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Dynavax Technologies
- Modality
- Small Molecules, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
A combination therapy consisting of SD-101 (a TLR9 agonist), paclitaxel (a taxane chemotherapy), and pembrolizumab (an anti-PD-1 monoclonal antibody). SD-101 activates plasmacytoid dendritic cells to produce interferon-alpha and enhances antigen presentation, paclitaxel provides direct cytotoxic effects against tumor cells, and pembrolizumab blocks the PD-1 pathway to enhance T-cell mediated anti-tumor immune responses.
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TLR9 (Toll-like receptor 9)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on SD-101 + paclitaxel + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SD-101 + paclitaxel + pembrolizumab.